Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
Value and Efficacy of Transcranial Direct Current Stimulation in the Cognitive Rehabilitation: A Critical Review Since 2000.
Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations.
Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI.
Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis (ITT-PMS)
European Medicines Agency
Genzyme’s Lemtrada Recommended for Reimbursement on NHS by the National Institute for Health and Care Excellence (NICE)
Multiple sclerosis immunology: The healthy immune system vs the MS immune system.
Roche's MabThera approved for two vasculitis indications in UK
Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolomod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation.
Small internal jugular veins with restricted outflow are associated with severe multiple sclerosis: a sonographer-blinded, case--control ultrasound study.
National Cancer Institute Search for Clinical Trials
Trimesta in relapsing-remitting multiple sclerosis patients (Phase II)
Bench to bedside: tempering antigen-presenting cells in multiple sclerosis.
Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model.
Efficacy and Tolerability of BAF312 in Patients With Polymyositis
Varicella zoster-associated retinal and central nervous system vasculitis in a patient with multiple sclerosis treated with natalizumab.
Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
Receptos Completes Enrollment of RADIANCE Phase 3 Trial of Ozanimod in Relapsing Multiple Sclerosis
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Dynamic imaging of individual remyelination profiles in multiple sclerosis.
Physicians from Accentia and Johns Hopkins University present plans for new MS drug study for Cyrevia
2-chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells.
GeNeuro Successful Phase 2a Clinical Study Reinforces Novel Approach to Treat Multiple Sclerosis: Patients Receiving First in Class GNbAC1 Mab Are Stable After One Year
Generic interferon-beta

Pages